eASCs

October 24, 2017October 24, 2017

TiGenix Potential Therapy for Crohn’s-related Perianal Fistulas Gets FDA Approval

News

The U.S. Food and Drug Administration (FDA) has granted TiGenix orphan drug designation for its lead candidate Cx601, which aims to treat perianal fistulas caused by Crohn’s disease in patients who have ... Read more

July 14, 2016July 14, 2016

Takeda Acquires Rights to Cx601, Possible Stem Cell Therapy for Perianal Fistulas in Crohn’s Patients

News

Takeda Pharmaceuticals has entered an exclusive licensing agreement with TiGenix to develop and commercialize Cx601 as a treatment for complex perianal fistulas in patients with Crohn’s disease. The agreement applies to Europe, ... Read more

February 17, 2015February 17, 2015

TiGenix And Lonza Partner For Complex Perianal Fistulas In Crohn’s Disease Treatment

Crohn's Disease, News

TiGenix, an advanced biotechnological company committed to developing and marketing new therapeutics from allogeneic expanded adipose-derived stem cells (eASCs) for autoimmune and inflammatory diseases, together with Lonza, a leading and global company of ... Read more